Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cassava Sciences Inc.

www.cassavasciences.com

Latest From Cassava Sciences Inc.

Cassava Starts Second Alzheimer's Study After PT-125 Effects Multiple Biomarkers

The company formerly known as Pain Therapeutics revealed a 100% response rate in a small Phase IIa study and hopes to confirm the novel drug's effects on all biomarkers tested in Phase IIb.

Clinical Trials Neurology

Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results

Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.

Financing Business Strategies

Tech Transfer Roundup: Mustang, Nationwide Children’s Hospital Collaborate In Pediatric Glioblastoma

Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.

Companies Deals

Opioid Sponsors Enter 2019 At A Crossroads

Recent regulatory trends at US FDA offer no clear path to success for sponsors developing opioids. As 2018 concludes with only one approval and at least five rejections, firms will need new strategies if they hope to bring the 

Research & Development Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Pain Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cassava Sciences Inc.
  • Senior Management
  • Remi Barbier, Chmn., Pres. & CEO
    Eric Schoen, CFO
    Nadav Friedmann, MD, PhD, CMO & COO
  • Contact Info
  • Cassava Sciences Inc.
    Phone: (512) 501-2444
    7801 N. Capital of Texas Hwy.
    Ste. 260
    Austin, TX 78731
    USA
UsernamePublicRestriction

Register